{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:19:01Z","timestamp":1761628741700,"version":"build-2065373602"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Project for Discipline Ability Enhancement of the Second Affiliated Hospital of Army Medical University"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104476"],"award-info":[{"award-number":["82104476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s41669-025-00604-z","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:48:13Z","timestamp":1757414893000},"page":"887-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China"],"prefix":"10.1007","volume":"9","author":[{"given":"Lulu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenqingyun","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"18","key":"604_CR1","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1056\/NEJMc1310369","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI. Herpes zoster. N Engl J Med. 2013;369(18):1766\u20137. https:\/\/doi.org\/10.1056\/NEJMc1310369.","journal-title":"N Engl J Med"},{"issue":"16","key":"604_CR2","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","volume":"371","author":"RW Johnson","year":"2014","unstructured":"Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526\u201333. https:\/\/doi.org\/10.1056\/NEJMcp1403062.","journal-title":"N Engl J Med"},{"issue":"6","key":"604_CR3","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"issue":"1","key":"604_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/s1473-3099(03)00857-0","volume":"4","author":"SL Thomas","year":"2004","unstructured":"Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26\u201333. https:\/\/doi.org\/10.1016\/s1473-3099(03)00857-0.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"604_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40520-019-01374-5","volume":"33","author":"PO Lang","year":"2021","unstructured":"Lang PO, Aspinall R. Vaccination for quality of life: herpes-zoster vaccines. Aging Clin Exp Res. 2021;33(4):1113\u201322. https:\/\/doi.org\/10.1007\/s40520-019-01374-5.","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"604_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","volume":"17","author":"D van Oorschot","year":"2021","unstructured":"van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccines Immunother. 2021;17(6):1714\u201332. https:\/\/doi.org\/10.1080\/21645515.2020.1847582.","journal-title":"Hum Vaccines Immunother"},{"issue":"12","key":"604_CR7","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806\u201321. https:\/\/doi.org\/10.1016\/j.mayocp.2017.10.009.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"604_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/14787210.2020.1792290","volume":"19","author":"D Yin","year":"2021","unstructured":"Yin D, Van Oorschot D, Jiang N, et al. A systematic literature review to assess the burden of herpes zoster disease in China. Expert Rev Anti-Infect Ther. 2021;19(2):165\u201379. https:\/\/doi.org\/10.1080\/14787210.2020.1792290.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"604_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2022.100145","volume":"10","author":"ZW Li","year":"2022","unstructured":"Li ZW, Yin CN, Wang HT, et al. Incidence trend and disease burden of seven vaccine-preventable diseases in Shandong province, China, 2013\u20132017: findings from a population-based observational study. Vaccine X. 2022;10: 100145. https:\/\/doi.org\/10.1016\/j.jvacx.2022.100145.","journal-title":"Vaccine X"},{"issue":"11","key":"604_CR10","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1080\/21645515.2018.1489193","volume":"14","author":"L Lu","year":"2018","unstructured":"Lu L, Suo L, Li J, Pang X. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. Hum Vaccines Immunother. 2018;14(11):2632\u20135. https:\/\/doi.org\/10.1080\/21645515.2018.1489193.","journal-title":"Hum Vaccines Immunother"},{"issue":"22","key":"604_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384. https:\/\/doi.org\/10.1056\/NEJMoa051016.","journal-title":"N Engl J Med"},{"issue":"6","key":"604_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900\u20139. https:\/\/doi.org\/10.1093\/cid\/ciu918.","journal-title":"Clin Infect Dis"},{"issue":"22","key":"604_CR13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","journal-title":"N Engl J Med"},{"issue":"11","key":"604_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70\u00a0years of age or older. N Engl J Med. 2016;375(11):1019\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1603800.","journal-title":"N Engl J Med"},{"issue":"6","key":"604_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3760\/cma.j.cn112338-20221125-00998","volume":"44","author":"M Wang","year":"2023","unstructured":"Wang M, Long C, Hu MZ, et al. A study on knowledge, attitude, and vaccination behavior of herpes zoster vaccine among urban residents in selected areas of China. Chin J Epidemiol. 2023;44(6):899\u2013904. https:\/\/doi.org\/10.3760\/cma.j.cn112338-20221125-00998.","journal-title":"Chin J Epidemiol"},{"key":"604_CR16","unstructured":"Analysis of the development trend of herpes zoster vaccine in China and Future Investment Forecast Report (2025\u20132032). https:\/\/www.chinabaogao.com\/baogao\/202501\/739904.html#r_contents. Accessed 17 June 2025."},{"key":"604_CR17","doi-asserted-by":"publisher","DOI":"10.2196\/43893","volume":"9","author":"Q Wang","year":"2023","unstructured":"Wang Q, Yang L, Li L, Liu C, Jin H, Lin L. Willingness to vaccinate against herpes zoster and its associated factors across WHO regions: global systematic review and meta-analysis. JMIR Public Health Surveill. 2023;9: e43893. https:\/\/doi.org\/10.2196\/43893.","journal-title":"JMIR Public Health Surveill"},{"issue":"Nov 2","key":"604_CR18","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1080\/21645515.2021.1960137","volume":"17","author":"X Lu","year":"2021","unstructured":"Lu X, Lu J, Zhang F, et al. Low willingness to vaccinate against herpes zoster in a Chinese metropolis. Hum Vaccines Immunother. 2021;17(Nov 2):4163\u201370. https:\/\/doi.org\/10.1080\/21645515.2021.1960137.","journal-title":"Hum Vaccines Immunother"},{"key":"604_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126975","volume":"54","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhao T, Cai X, et al. Are health education effective to improve herpes zoster vaccine willingness in vulnerable elderly. Vaccine. 2025;54: 126975. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126975.","journal-title":"Vaccine"},{"issue":"Nov","key":"604_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.amepre.2023.05.007","volume":"65","author":"M Jiang","year":"2023","unstructured":"Jiang M, Yao X, Peng J, et al. Cost-effectiveness of recombinant zoster vaccine for adults aged \u2265\u00a050\u00a0years in China. Am J Prev Med. 2023;65(Nov):818\u201326. https:\/\/doi.org\/10.1016\/j.amepre.2023.05.007.","journal-title":"Am J Prev Med"},{"issue":"2","key":"604_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","volume":"178","author":"P Le","year":"2018","unstructured":"Le P, Rothberg MB. Cost-effectiveness of the adjuvanted Herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248\u201358. https:\/\/doi.org\/10.1001\/jamainternmed.2017.7431.","journal-title":"JAMA Intern Med"},{"key":"604_CR22","doi-asserted-by":"publisher","unstructured":"Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70(8). https:\/\/doi.org\/10.18637\/jss.v070.i08","DOI":"10.18637\/jss.v070.i08"},{"key":"604_CR23","unstructured":"National Bureau of Statistics. China Population Census [Yearbook]. https:\/\/www.stats.gov.cn\/sj\/pcsj\/rkpc\/7rp\/zk\/indexch.htm. Accessed 31 May 2024."},{"issue":"06","key":"604_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.16505\/j.2095-0136.2019.0070","volume":"9","author":"F Lu","year":"2019","unstructured":"Lu F, Xu C, Tian T, Pei S, Sui H, Yin D. Incidence of herpes zoster in Yichang city of China in 2016. Chin J Viral Dis. 2019;9(06):475\u20138. https:\/\/doi.org\/10.16505\/j.2095-0136.2019.0070.","journal-title":"Chin J Viral Dis"},{"issue":"2","key":"604_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jinf.2020.12.013","volume":"82","author":"X Sun","year":"2021","unstructured":"Sun X, Wei Z, Lin H, Jit M, Li Z, Fu C. Incidence and disease burden of herpes zoster in the population aged \u226550\u00a0years in China: data from an integrated health care network. J Infect. 2021;82(2):253\u201360. https:\/\/doi.org\/10.1016\/j.jinf.2020.12.013.","journal-title":"J Infect"},{"issue":"6","key":"604_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2340\/00015555-0729","volume":"89","author":"JS Jih","year":"2009","unstructured":"Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89(6):612\u20136. https:\/\/doi.org\/10.2340\/00015555-0729.","journal-title":"Acta Derm Venereol"},{"issue":"04","key":"604_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.19914\/j.cjvi.2019.04.016","volume":"25","author":"W Jiang","year":"2019","unstructured":"Jiang W, Li G, Xu Y, et al. Epidemiological characteristics of herpes zoster in urban areas of Yichang city during 2016\u20132017 based on the Yichang Big Data Platform for Health Management. Chin J Vaccines Immun. 2019;25(04):432\u20135. https:\/\/doi.org\/10.19914\/j.cjvi.2019.04.016.","journal-title":"Chin J Vaccines Immun"},{"issue":"6","key":"604_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","volume":"12","author":"L Teng","year":"2022","unstructured":"Teng L, Mizukami A, Ng C, et al. Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults. Dermatol Ther (Heidelb). 2022;12(6):1447\u201367. https:\/\/doi.org\/10.1007\/s13555-022-00744-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"604_CR29","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1080\/21645515.2021.1932216","volume":"17","author":"C Lee","year":"2021","unstructured":"Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50\u00a0years and older in Beijing. Hum Vaccines Immunother. 2021;17(10):3735\u201346. https:\/\/doi.org\/10.1080\/21645515.2021.1932216.","journal-title":"Hum Vaccines Immunother"},{"issue":"8","key":"604_CR30","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/cid\/ciab629","volume":"74","author":"C Boutry","year":"2022","unstructured":"Boutry C, Hastie A, Diez-Domingo J, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459\u201367. https:\/\/doi.org\/10.1093\/cid\/ciab629.","journal-title":"Clin Infect Dis"},{"issue":"Dec 2","key":"604_CR31","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","volume":"17","author":"D Curran","year":"2021","unstructured":"Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(Dec 2):5296\u2013303. https:\/\/doi.org\/10.1080\/21645515.2021.2002085.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"604_CR32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/cis638","volume":"55","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320\u20138. https:\/\/doi.org\/10.1093\/cid\/cis638.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"604_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11606-016-3844-6","volume":"32","author":"P Le","year":"2017","unstructured":"Le P, Rothberg MB. Determining the optimal vaccination schedule for Herpes zoster: a cost-effectiveness analysis. J Gen Intern Med. 2017;32(2):159\u201367. https:\/\/doi.org\/10.1007\/s11606-016-3844-6.","journal-title":"J Gen Intern Med"},{"issue":"7","key":"604_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359\u00a0years. Clin Infect Dis. 2012;54(7):922\u20138. https:\/\/doi.org\/10.1093\/cid\/cir970.","journal-title":"Clin Infect Dis"},{"key":"604_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.puhe.2015.10.009","volume":"131","author":"P Lei","year":"2016","unstructured":"Lei P, Xu L, Nwaru BI, Long Q, Wu Z. Social networks and health-related quality of life among Chinese old adults in urban areas: results from 4th National Household Health Survey. Public Health. 2016;131:27\u201339. https:\/\/doi.org\/10.1016\/j.puhe.2015.10.009.","journal-title":"Public Health"},{"issue":"6","key":"604_CR36","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s12325-021-01717-7","volume":"38","author":"J D\u00edez-Domingo","year":"2021","unstructured":"D\u00edez-Domingo J, Curran D, Cambronero MDR, Garcia-Martinez JA, Matthews S. Economic burden and impact on quality of life of herpes zoster in Spanish adults aged 50\u00a0years or older: a prospective cohort study. Adv Ther. 2021;38(6):3325\u201341. https:\/\/doi.org\/10.1007\/s12325-021-01717-7.","journal-title":"Adv Ther"},{"key":"604_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1477-7525-12-92","volume":"12","author":"M Serpell","year":"2014","unstructured":"Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual Life Outcomes. 2014;12:92. https:\/\/doi.org\/10.1186\/1477-7525-12-92.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"604_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00019053-200826030-00006","volume":"26","author":"TA Lieu","year":"2008","unstructured":"Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics. 2008;26(3):235\u201349. https:\/\/doi.org\/10.2165\/00019053-200826030-00006.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"604_CR39","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcma.2017.06.024","volume":"81","author":"CC Tseng","year":"2018","unstructured":"Tseng CC, Lai MT, Wu CC, Yuan SP, Ding YF. Cost-effectiveness analysis of endoscopic tympanoplasty versus microscopic tympanoplasty for chronic otitis media in Taiwan. J Chin Med Assoc. 2018;81(3):284\u201390. https:\/\/doi.org\/10.1016\/j.jcma.2017.06.024.","journal-title":"J Chin Med Assoc"},{"key":"604_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.647725","volume":"9","author":"X Sun","year":"2021","unstructured":"Sun X, Tang Y, Ma X, et al. Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine program for the elderly aged 60\u00a0years or older in Shanghai, China. Front Public Health. 2021;9: 647725. https:\/\/doi.org\/10.3389\/fpubh.2021.647725.","journal-title":"Front Public Health"},{"issue":"5","key":"604_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jval.2014.05.007","volume":"17","author":"GG Liu","year":"2014","unstructured":"Liu GG, Wu H, Li M, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17(5):597\u2013604. https:\/\/doi.org\/10.1016\/j.jval.2014.05.007.","journal-title":"Value Health"},{"key":"604_CR42","unstructured":"Chinese drug price of drug centralized bid procurement. https:\/\/db.yaozh.com\/yaopinzhongbiao. Accessed 31 May 2024."},{"issue":"5","key":"604_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3760\/cma.j.issn.0253-9624.2019.05.013","volume":"53","author":"LD Suo","year":"2019","unstructured":"Suo LD, Zhao D, Pan JB, et al. Analysis of herpes zoster incidence and hospitalization in three areas of Beijing in 2015 based on health information system of medical institutions. Chin J Prev Med. 2019;53(5):503\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-9624.2019.05.013.","journal-title":"Chin J Prev Med"},{"key":"604_CR44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/ceor.S203920","volume":"11","author":"SY Yu","year":"2019","unstructured":"Yu SY, Fan BF, Yang F, et al. Patient and economic burdens of postherpetic neuralgia in China. Clinicoecon Outcomes Res. 2019;11:539\u201350. https:\/\/doi.org\/10.2147\/ceor.S203920.","journal-title":"Clinicoecon Outcomes Res"},{"key":"604_CR45","unstructured":"China Health Statistical Yearbook. China Union Medical College University Press; 2021."},{"issue":"3","key":"604_CR46","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/s2214-109x(22)00554-x","volume":"11","author":"H Liu","year":"2023","unstructured":"Liu H, Li R, Zhang Y, et al. Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a cost-effectiveness analysis. Lancet Glob Health. 2023;11(3):e456\u201365. https:\/\/doi.org\/10.1016\/s2214-109x(22)00554-x.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"604_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22177-6","volume":"25","author":"L Yin","year":"2025","unstructured":"Yin L, Liu J, Zhang J, et al. Economic burden due to hearing loss among individuals in Hebei, China. BMC Public Health. 2025;25(1): 1080. https:\/\/doi.org\/10.1186\/s12889-025-22177-6.","journal-title":"BMC Public Health"},{"issue":"5","key":"604_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/ane.13485","volume":"144","author":"XP Ma","year":"2021","unstructured":"Ma XP, Li JM, Zhou D, Yang R. Direct economic burden of patients with tuberculous meningitis in western China. Acta Neurol Scand. 2021;144(5):535\u201345. https:\/\/doi.org\/10.1111\/ane.13485.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"604_CR49","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/svn-2023-002296","volume":"9","author":"W Lv","year":"2024","unstructured":"Lv W, Wang A, Wang Q, et al. One-year direct and indirect costs of ischaemic stroke in China. Stroke Vasc Neurol. 2024;9(4):380\u20139. https:\/\/doi.org\/10.1136\/svn-2023-002296.","journal-title":"Stroke Vasc Neurol"},{"issue":"2","key":"604_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3760\/cma.j.cn112150-20211125-01085","volume":"56","author":"WY Zhang","year":"2022","unstructured":"Zhang WY, Liu SN, Sun HY, et al. Study of incidence and economic burden of herpes zoster based on community investigation among the aged in Laiwu district, Jinan city, Shandong Province of China. Zhonghua Yu Fang Yi Xue Za Zhi. 2022;56(2):119\u201324. https:\/\/doi.org\/10.3760\/cma.j.cn112150-20211125-01085.","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"604_CR51","unstructured":"China Foreign Exchange Trade System. https:\/\/www.chinamoney.com.cn\/chinese\/. Accessed 31 May 2024."},{"key":"604_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue X, Li Y, Wu J, Guo JJ. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1\u20135. https:\/\/doi.org\/10.1016\/j.vhri.2020.07.580.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"604_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0037.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"604_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, Steuten L, Knies S, et al. Value of information analysis for research decisions-an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(2):139\u201350. https:\/\/doi.org\/10.1016\/j.jval.2020.01.001.","journal-title":"Value Health"},{"issue":"3","key":"604_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","volume":"23","author":"C Rothery","year":"2020","unstructured":"Rothery C, Strong M, Koffijberg HE, et al. Value of information analytical methods: report 2 of the ISPOR value of information analysis emerging good practices task force. Value Health. 2020;23(3):277\u201386. https:\/\/doi.org\/10.1016\/j.jval.2020.01.004.","journal-title":"Value Health"},{"issue":"1","key":"604_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2198-y","volume":"17","author":"LK Chen","year":"2017","unstructured":"Chen LK, Arai H, Chen LY, et al. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific. BMC Infect Dis. 2017;17(1): 213. https:\/\/doi.org\/10.1186\/s12879-017-2198-y.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"604_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10\u00a0years after initial vaccination. Open Forum Infect Dis. 2022;9(10): ofac485. https:\/\/doi.org\/10.1093\/ofid\/ofac485.","journal-title":"Open Forum Infect Dis"},{"issue":"33","key":"604_CR58","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005.","journal-title":"Vaccine"},{"issue":"5","key":"604_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","volume":"17","author":"A McGirr","year":"2019","unstructured":"McGirr A, Van Oorschot D, Widenmaier R, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723\u201332. https:\/\/doi.org\/10.1007\/s40258-019-00491-6.","journal-title":"Appl Health Econ Health Policy"},{"issue":"27","key":"604_CR60","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1016\/j.vaccine.2019.05.006","volume":"37","author":"SL Hoshi","year":"2019","unstructured":"Hoshi SL, Seposo X, Shono A, Okubo I, Kondo M. Cost-effectiveness of recombinant zoster vaccine (RZV) and varicella vaccine live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine. 2019;37(27):3588\u201397. https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.006.","journal-title":"Vaccine"},{"issue":"6","key":"604_CR61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciw854","volume":"64","author":"HS Izurieta","year":"2017","unstructured":"Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65\u00a0years and older. Clin Infect Dis. 2017;64(6):785\u201393. https:\/\/doi.org\/10.1093\/cid\/ciw854.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"604_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420","volume":"10","author":"SM Langan","year":"2013","unstructured":"Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4): e1001420. https:\/\/doi.org\/10.1371\/journal.pmed.1001420.","journal-title":"PLoS Med"},{"key":"604_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076321","volume":"383","author":"NP Klein","year":"2023","unstructured":"Klein NP, Bartlett J, Fireman B, et al. Effectiveness of the live zoster vaccine during the 10\u00a0years following vaccination: real world cohort study using electronic health records. BMJ. 2023;383: e076321. https:\/\/doi.org\/10.1136\/bmj-2023-076321.","journal-title":"BMJ"},{"issue":"2","key":"604_CR64","doi-asserted-by":"publisher","first-page":"189","DOI":"10.7326\/m23-2023","volume":"177","author":"O Zerbo","year":"2024","unstructured":"Zerbo O, Bartlett J, Fireman B, et al. Effectiveness of recombinant zoster vaccine against Herpes zoster in a real-world setting. Ann Intern Med. 2024;177(2):189\u201395. https:\/\/doi.org\/10.7326\/m23-2023.","journal-title":"Ann Intern Med"},{"issue":"1","key":"604_CR65","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12916-018-1213-5","volume":"16","author":"PT de Boer","year":"2018","unstructured":"de Boer PT, van Lier A, de Melker H, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228. https:\/\/doi.org\/10.1186\/s12916-018-1213-5.","journal-title":"BMC Med"},{"issue":"34","key":"604_CR66","doi-asserted-by":"publisher","first-page":"E932","DOI":"10.1503\/cmaj.190274","volume":"191","author":"M Drolet","year":"2019","unstructured":"Drolet M, Zhou Z, Sauvageau C, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191(34):E932\u2013E939. https:\/\/doi.org\/10.1503\/cmaj.190274.","journal-title":"CMAJ"},{"issue":"1","key":"604_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/jiv480","volume":"213","author":"MJ Levin","year":"2016","unstructured":"Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10\u00a0years after the first dose among older adults. J Infect Dis. 2016;213(1):14\u201322. https:\/\/doi.org\/10.1093\/infdis\/jiv480.","journal-title":"J Infect Dis"},{"issue":"1","key":"604_CR68","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.amepre.2020.01.017","volume":"59","author":"PJ Lu","year":"2020","unstructured":"Lu PJ, Hung MC, Srivastav A, Williams WW, Dooling KL. Shingles vaccination of U.S. adults aged 50\u201359\u00a0years and \u226560\u00a0years before recommendations for use of recombinant zoster vaccine. Am J Prev Med. 2020;59(1):21\u201331. https:\/\/doi.org\/10.1016\/j.amepre.2020.01.017.","journal-title":"Am J Prev Med"},{"issue":"8","key":"604_CR69","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/gerona\/gly150","volume":"74","author":"D Curran","year":"2019","unstructured":"Curran D, Oostvogels L, Heineman T, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50\u00a0years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231\u20138. https:\/\/doi.org\/10.1093\/gerona\/gly150.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"19\u201320","key":"604_CR70","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1016\/s0264-410x(02)00180-9","volume":"20","author":"M Brisson","year":"2002","unstructured":"Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20(19\u201320):2500\u20137. https:\/\/doi.org\/10.1016\/s0264-410x(02)00180-9.","journal-title":"Vaccine"},{"issue":"6","key":"604_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066485","volume":"8","author":"B Ogunjimi","year":"2013","unstructured":"Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS ONE. 2013;8(6): e66485. https:\/\/doi.org\/10.1371\/journal.pone.0066485.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00604-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00604-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:13:23Z","timestamp":1761628403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00604-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00604-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This economic analysis was based on a literature review and modeling techniques; this study did not require approval from an Institutional Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The cost-effectiveness model can be obtained from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors declare that they have no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was supported by the Project for Discipline Ability Enhancement of the Second Affiliated Hospital of Army Medical University, the National Natural Science Foundation of China (No. 82104476)\u00a0and Chongqing Talent Program\u00a0(No.\u00a0CQYC20210303411).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RZ and ZZ conceived and administered the study. LL, YS, and QZ conducted the analysis, drafted the manuscript and interpreted the results. YS, LW, ZS, and MC substantively revised the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}